Table 1.
Current redox clinical investigations for the treatment of neurodegenerative diseases.
Redox therapy | Clinical application |
---|---|
Vitamin E | Alzheimer's disease [20, 21] Parkinson's disease [22, 23] Multiple sclerosis [24, 25] |
| |
Polyphenols | Parkinson's disease [22, 23] Multiple sclerosis [24, 25] Hereditary spastic paraplegia [ClinicalTrials.gov: NCT02314208] |
| |
Coenzyme Q10 | Parkinson's disease [26–29] Multiple sclerosis |
| |
MPAC (i.e., clioquinol) |
Alzheimer's disease [30–32] Parkinson's disease [33, 34] |
| |
ω-3 PUFAs | Multiple sclerosis [35, 36] |
| |
Metalloporphyrins | Amyotrophic lateral sclerosis [37] |
| |
Pramipexole (i.e., KNS-760704) |
Amyotrophic lateral sclerosis [38] |
MPAC: metal protein attenuating compounds; PUFAs: polyunsaturated fatty acids.